Aspire Biopharma Hldgs Inc.
13F holders, Q1 2026 (March 31)13holders
$1.03avg. 13F price*
At the end of Q1 2026, 13 institutions reported holding Aspire Biopharma Hldgs Inc. in their 13F filings. The largest holders were UBS Group AG ($197K), Morgan Stanley ($79K) and Geode Capital Management, LLC ($45K).
- Company
- Aspire Biopharma Hldgs Inc.
- CUSIP
- 738920206
- Latest filing quarter
- Q1 2026
Total Exit/New Position Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 11 | $352K |
| Exits | 0 | $0 |
Ownership 13 holders
| UBS Group AG | 0.00% | New | 191,499 | $197K |
| Morgan Stanley | 0.00% | New | 76,955 | $79K |
| Geode Capital Management, LLC | 0.00% | New | 43,384 | $45K |
| Crewe Advisors LLC | 0.00% | New | 20,335 | $21K |
| Vanguard Capital Management LLC | 0.00% | — | 7,859 | $8K |
| Toronto Dominion Bank | 0.00% | New | 5,000 | $5K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 2,856 | $3K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 2,174 | $2K |
| Citigroup Inc. | 0.00% | New | 1,846 | $2K |
| Avion Wealth | 0.00% | New | 1,352 | $1K |
| Osaic Holdings, Inc. | 0.00% | New | 2 | $2 |
| SBI Securities Co., Ltd. | 0.00% | New | 1 | $1 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 1 | $1 |
"% of holder's portfolio" is ASPIRE BIOPHARMA HLDGS INC's weight in each manager's 13F, not the share of Aspire Biopharma Hldgs Inc. the manager owns.